Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2352Neoplasms 1707Prostatic Neoplasms 1197Lung Neoplasms 923Colorectal Neoplasms 882Carcinoma, Non-Small-Cell Lung 867Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 577Multiple Myeloma 549Carcinoma, Hepatocellular 516Brain Neoplasms 513Neoplasm Metastasis 459Head and Neck Neoplasms 454Melanoma 414Ovarian Neoplasms 413Glioblastoma 402Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 375Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 361Rectal Neoplasms 341Recurrence 336Sarcoma 325Hematologic Neoplasms 323Colonic Neoplasms 323Lymphoma 319Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 283Urinary Bladder Neoplasms 281Glioma 278

Interventions

Cobicistat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × BRAF V600E Mutation × 1 year × Clear all
NCT06610682 2025-12-10

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Recruiting
15 enrolled

BRAF V600E Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡